130290-78-7

Basic information

• Product Name: Cis-4-methoxycyclohexanamine
• Synonyms: Cis-4-methoxycyclohexanamine;Cis-4-methoxy-cyclohexylamine;CIS-4-METHOXYCYCLOHEXANAMINE,,(1S,4S)-4-METHOXYCYCLOHEXAN-1-AMINE
• CAS NO: 130290-78-7
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2001
• Mol File: 130290-78-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 174.5±33.0 °C(Predicted)
• Appearance: /
• Density: 0.94±0.1 g/cm3(Predicted)
• PKA: 10.38±0.70(Predicted)
• CAS DataBase Reference: Cis-4-methoxycyclohexanamine(CAS DataBase Reference)
• NIST Chemistry Reference: Cis-4-methoxycyclohexanamine(130290-78-7)
• EPA Substance Registry System: Cis-4-methoxycyclohexanamine(130290-78-7)

Safety Data

• Hazardous Substances Data: 130290-78-7(Hazardous Substances Data)

Usage

General Description

Cis-4-methoxycyclohexanamine is an organic compound with the molecular formula C7H15NO. It is classified as a cycloalkylamine, with a methoxy group attached to the fourth carbon of the cyclohexane ring in the cis configuration. Cis-4-methoxycyclohexanamine is commonly used in organic synthesis and pharmaceutical research due to its versatile reactivity and potential biological activity. It has been studied for its potential applications as a pharmaceutical intermediate, as well as its potential effects on the central nervous system. Additionally, cis-4-methoxycyclohexanamine has been investigated for its potential use in the development of new drugs and therapeutic agents.

Upstream product

• 104-94-9 4-methoxy-aniline 
• 150-76-5 4-methoxy-phenol 
• 61367-42-8 4-Methoxycyclohexanon-oxim 

Downstream Products

• 61367-29-1 1-(2-Chloro-ethyl)-3-(4-methoxy-cyclohexyl)-urea 
• 61367-30-4 C₁₀H₁₈ClN₃O₃ 

Relevant articles and documents

Ceria supported Ru0-Ruδ+ clusters as efficient catalyst for arenes hydrogenation

Selective hydrogenation of aromatic amines, especially chemicals such as aniline and bis(4-aminocyclohexyl)methane for non-yellowing polyurethane, is of particular interests due to the extensive applications. To conquer the existing difficulties in selective hydrogenation, the Ru0-Ruδ+/CeO2 catalyst with solid frustrated Lewis pairs was developed for aromatic amines hydrogenation with excellent activity and selectivity under relative milder conditions. The morphology, electronic and chemical properties, especially the Ru0-Ruδ+ clusters and reducible ceria were characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM), scanning electronic microscopy (SEM), X-ray photoelectron spectroscopy (XPS), CO2 temperature programmed desorption (CO2-TPD), H2 temperature programmed reduction (H2-TPR), H2 diffuse reflectance Fourier transform infrared spectroscopy (H2-DRIFT), Raman, etc. The 2% Ru/CeO2 catalyst exhibited good conversion of 95% and selectivity greater than 99% toward cyclohexylamine. The volcano curve describing the activity and Ru state was found. Owning to the “acidic site isolation” by surrounding alkaline sites, condensation between the neighboring amine molecules could be effectively suppressed. The catalyst also showed good stability and applicability for other aromatic amines and heteroarenes containing different functional groups.

Synthesis of analogues of N (2 chloroethyl) N' trans 4 methylcyclohexyl) N nitrosourea for evaluation as anticancer agents

The superior activity of N (2 chloroethyl) N' (trans 4 methylcyclohexyl) N nitrosourea (MeCCNU) against advanced murine Lewis lung carcinoma in comparisons with the cis form and other nitrosoureas prompted the synthesis of a number of MeCCNU analogues, including several cis trans pairs. The methyl group was replaced by a variety of substituents (CO2H, CH2CO2H, CO2Me, CH2OAc, CH2Cl, OMe); the trans 3 methylcyclohexyl, cis 2 methyl 1,3 dithian 5 yl, cis and trans 2 methyl 1,3 dithian 5 yl tetraoxide, and 1 methylhexyl (open chain) analogues were also prepared. Preliminary tests against murine leukemia L1210 revealed therapeutic indices (ED50/LD10) ranging from 0.26 to 0.79; all but 3 analogues effected 50% cure rates at nontoxic doses, the open chain analogue being one of the least active. In terms of therapeutic index, diequatorial (trans 4) isomers were, with one exception, as active as or, in 4 of the 8 examples, somewhat more active than the corresponding axial equatorial (cis 4) isomers. In this series, 4 of the 5 2-fluoroethyl analogues prepared were clearly inferior to the corresponding 2 chloroethyl analogues.